John Fesko Sells 295 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 295 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $267.99, for a total value of $79,057.05. Following the completion of the transaction, the insider owned 183,774 shares in the company, valued at $49,249,594.26. This trade represents a 0.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Tuesday, July 28th, John Fesko sold 931 shares of Natera stock. The shares were sold at an average price of $254.07, for a total value of $236,539.17.
• On Monday, July 27th, John Fesko sold 782 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $203,703.18.
• On Tuesday, May 26th, John Fesko sold 1,438 shares of Natera stock. The stock was sold at an average price of $202.84, for a total transaction of $291,683.92.

Natera Stock Performance

Shares of Natera stock traded down $0.61 during midday trading on Wednesday, reaching $274.58. 1,128,660 shares of the company’s stock traded hands, compared to its average volume of 1,104,859. Natera, Inc. has a 52 week low of $135.75 and a 52 week high of $288.04. The company’s 50 day simple moving average is $251.03 and its 200 day simple moving average is $222.85. The company has a market cap of $39.32 billion, a price-to-earnings ratio of -168.45 and a beta of 1.51.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in NTRA. Robinhood Asset Management LLC acquired a new stake in shares of Natera in the fourth quarter worth $12,981,000. UBS Group AG boosted its holdings in Natera by 19.4% in the 4th quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock valued at $100,538,000 after purchasing an additional 71,355 shares during the period. ABN Amro Investment Solutions grew its position in Natera by 44.6% in the 1st quarter. ABN Amro Investment Solutions now owns 9,346 shares of the medical research company’s stock worth $1,869,000 after purchasing an additional 2,883 shares during the last quarter. Fifth Third Bancorp increased its holdings in shares of Natera by 3,373.1% during the 1st quarter. Fifth Third Bancorp now owns 11,253 shares of the medical research company’s stock worth $2,251,000 after purchasing an additional 10,929 shares during the period. Finally, Teacher Retirement System of Texas raised its position in shares of Natera by 286.8% during the fourth quarter. Teacher Retirement System of Texas now owns 65,717 shares of the medical research company’s stock valued at $15,055,000 after buying an additional 48,728 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

NTRA has been the subject of a number of analyst reports. Zacks Research cut Natera from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. TD Cowen reissued a “buy” rating on shares of Natera in a report on Wednesday, July 15th. Royal Bank Of Canada began coverage on Natera in a research note on Thursday, June 11th. They issued an “outperform” rating and a $275.00 price objective on the stock. The Goldman Sachs Group began coverage on Natera in a report on Friday, June 5th. They issued a “neutral” rating and a $245.00 target price for the company. Finally, UBS Group set a $260.00 target price on Natera in a research report on Wednesday, June 24th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $267.83.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.